Literature DB >> 27066855

Targeted resequencing of regulatory regions at schizophrenia risk loci: Role of rare functional variants at chromatin repressive states.

Javier González-Peñas1, Jorge Amigo2, Luis Santomé3, Beatriz Sobrino2, Julio Brenlla4, Santiago Agra4, Eduardo Paz4, Mario Páramo4, Ángel Carracedo2, Manuel Arrojo4, Javier Costas5.   

Abstract

There is mounting evidence that regulatory variation plays an important role in genetic risk for schizophrenia. Here, we specifically search for regulatory variants at risk by sequencing promoter regions of twenty-three genes implied in schizophrenia by copy number variant or genome-wide association studies. After strict quality control, a total of 55,206bp per sample were analyzed in 526 schizophrenia cases and 516 controls from Galicia, NW Spain, using the Applied Biosystems SOLiD System. Variants were filtered based on frequency from public databases, chromatin states from the RoadMap Epigenomics Consortium at tissues relevant for schizophrenia, such as fetal brain, mid-frontal lobe, and angular gyrus, and prediction of functionality from RegulomeDB. The proportion of rare variants at polycomb repressive chromatin state at relevant tissues was higher in cases than in controls. The proportion of rare variants with predicted regulatory role was significantly higher in cases than in controls (P=0.0028, OR=1.93, 95% C.I.=1.23-3.04). Combination of information from both sources led to the identification of an excess of carriers of rare variants with predicted regulatory role located at polycomb repressive chromatin state at relevant tissues in cases versus controls (P=0.0016, OR=19.34, 95% C.I.=2.45-2495.26). The variants are located at two genes affected by the 17q12 copy number variant, LHX1 and HNF1B. These data strongly suggest that a specific epigenetic mechanism, chromatin remodeling by histone modification during early development, may be impaired in a subset of schizophrenia patients, in agreement with previous data.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CNV; Chromatin remodeling; Next-generation sequencing; Polycomb; Rare variant; Single nucleotide variant

Mesh:

Substances:

Year:  2016        PMID: 27066855     DOI: 10.1016/j.schres.2016.03.029

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  4 in total

1.  Sex-specific transcriptional and proteomic signatures in schizophrenia.

Authors:  Jari Tiihonen; Marja Koskuvi; Markus Storvik; Ida Hyötyläinen; Yanyan Gao; Katja A Puttonen; Raisa Giniatullina; Ekaterina Poguzhelskaya; Ilkka Ojansuu; Olli Vaurio; Tyrone D Cannon; Jouko Lönnqvist; Sebastian Therman; Jaana Suvisaari; Jaakko Kaprio; Lesley Cheng; Andrew F Hill; Markku Lähteenvuo; Jussi Tohka; Rashid Giniatullin; Šárka Lehtonen; Jari Koistinaho
Journal:  Nat Commun       Date:  2019-09-02       Impact factor: 14.919

2.  Identification of the primate-specific gene BTN3A2 as an additional schizophrenia risk gene in the MHC loci.

Authors:  Yong Wu; Rui Bi; Chunhua Zeng; Changguo Ma; Chunli Sun; Jingzheng Li; Xiao Xiao; Ming Li; Deng-Feng Zhang; Ping Zheng; Nengyin Sheng; Xiong-Jian Luo; Yong-Gang Yao
Journal:  EBioMedicine       Date:  2019-05-24       Impact factor: 8.143

3.  Integrating Imaging Genomic Data in the Quest for Biomarkers of Schizophrenia Disease.

Authors:  Vince D Calhoun
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2017-09-04       Impact factor: 3.710

4.  Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa.

Authors:  L M Huckins; K Hatzikotoulas; L Southam; L M Thornton; J Steinberg; F Aguilera-McKay; J Treasure; U Schmidt; C Gunasinghe; A Romero; C Curtis; D Rhodes; J Moens; G Kalsi; D Dempster; R Leung; A Keohane; R Burghardt; S Ehrlich; J Hebebrand; A Hinney; A Ludolph; E Walton; P Deloukas; A Hofman; A Palotie; P Palta; F J A van Rooij; K Stirrups; R Adan; C Boni; R Cone; G Dedoussis; E van Furth; F Gonidakis; P Gorwood; J Hudson; J Kaprio; M Kas; A Keski-Rahkonen; K Kiezebrink; G-P Knudsen; M C T Slof-Op 't Landt; M Maj; A M Monteleone; P Monteleone; A H Raevuori; T Reichborn-Kjennerud; F Tozzi; A Tsitsika; A van Elburg; D A Collier; P F Sullivan; G Breen; C M Bulik; E Zeggini
Journal:  Mol Psychiatry       Date:  2017-07-25       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.